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Multiple myeloma (MM) is a neoplastic plasma-cell disorder.
This is characterized by clonal proliferation of malignant
plasma cells in the bone-marrow (BM) microenvironment,
monoclonal protein in blood or urine, and associated organ
dysfunction. The treatment options approved by FDA are
immune-modulatory agents, proteasome inhibitors, and
autologous stem cell transplantation (ASCT). Unfortunately,
MM remains uniformly fatal owing to intrinsic or acquired
drug resistance and the median survival time is 3 to 5 years.
Thus, there is a great need for novel strategies to combat MM.
The intimate relationship of myeloma cells to BM
microenvironment is “hallmark of myeloma”. The homing of
MM cells to the BM, mediated by the chemokine stromal cell-
derived factor-1α (SDF-1α) and its receptor CXCR4 has
important functional sequelae. The BM microenvironment
constituting cells secrete chemokines, cytokines, and growth
factors such as interleukin 6 (IL6), vascular endothelial growth
factor (VEGF), SDF-1α, and tumor necrosis factor α (TNFα) etc.
These growth factors either secreted by MM or BM
microenvironment cells (e.g. stromal cells) contribute in
activation of several signaling pathways including nuclear
factor-κB (NF-κB); phosphatidylinositol 3-kinase (PI3K)-Akt;
Ras-Raf-MAPK kinase (MEK)-extracellular signal regulated
kinase (ERK); and the Janus kinase 2 (JAK2)-signal transducer
and activator of transcription 3 (STAT3). Activation of these
pathways has been associated with increased expression of
several anti-apoptotic proteins such as Bcl-2, Bcl-xL, Mcl-1, and
XIAP. Collectively, these discoveries highlight that interaction
of MM cells to BM microenvironment not only promote
growth, survival and migration of MM cells, but also confer
resistance to conventional chemotherapy. We hypothesized
that an agent capable of inhibiting the migration of myeloma
cells to bone marrow and suppressing the expression of
survival protein Mcl-1 would be a better option for MM
treatment. We have synthesized a novel dual inhibitor of
CXCR4 and Mcl-1. Our in vitro data suggests that this molecule
inhibits the expression of CXCR4 and Mcl-1 and survival of MM
cells.
 MM cells are highly dependent on the bone marrow
(BM) microenvironment for growth and survival.1
 Migration of cells through the blood to the BM niches
requires active navigation, a process termed homing.
 One of the most extensively studied chemokines in
homing is stromal cell-derived factor 1α [SDF-1α; also
known as CXC chemokine ligand 12 (CXCL12)] and its
receptor, CXCR4.2
 The BM microenvironment constituting cells
secrete chemokines, cytokines, and growth factors
such as interleukin 6 (IL6), vascular endothelial
growth factor (VEGF), SDF-1α, and tumor necrosis factor α
(TNFα) etc. 3
 These growth factors contribute in activation of several
signaling pathways including nuclear factor-κB (NF-κB);
phosphatidylinositol 3-kinase (PI3K)-Akt; Ras-Raf-MAPK kinase
(MEK)-extracellular signal regulated kinase (ERK); and the
Janus kinase 2 (JAK2)-signal transducer and activator of
transcription 3 (STAT3). Activation of these pathways has been
associated with increased expression of several anti-apoptotic
proteins such as Bcl-2, Bcl-xL, Mcl-1, and XIAP. 4
 Mcl-1 is one of the most highly amplified genes in a variety
of human cancers including MM and contributes in drug
resistance.4 Thus, Mcl-1 becomes unique target to overcome
resistance in MM.
 Gambogic acid (GA) is a xanthone derived from the resin of
Garcinia hanburyi (also called mangosteen). We have
previously shown that GA inhibits CXCR4 in MM.5
 We modified GA by adding MCl-1 inhibitor moiety in order to
develop this molecule as a dual inhibitor of CXCR4 and Mcl-1.
We investigated whether the gambogic acid (GA) analog (s)
can modulate survival and drug resistance of MM cells.
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Figure 2. A, GA was docked onto CXCR4, and compared with AMD3100.
CXCR4 residues within 5 Å distance from the ligands are shown with gray
carbon atoms and ligands shown with green carbon atoms. Oxygen
atoms are colored red, nitrogen blue, and polar hydrogen white. B, GA
suppresses CXCR4 levels in a dose- and time- dependent manner. C,
Surface expression of CXCR4 in GA treated MM cells was determined by
flow cytometer.
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GA analog reduces cell viability and induces apoptosis through inhibition of Mcl-1
Figure 3. A, GA analogs reduce the survival of MM cells. MM cells (RPMI 8226 and U266) were treated with
different concentration of GA, and its analogs for 48h. Cell viabilities were assessed using MTT assay. As shown
in the figure treatment of GA and its analog effectively kill MM cells. Prism software was used to plot the graph.
B, Effect of GA analog on survival protein was investigated. The human MM RPMI 8226 cells were treated with
the indicated amount of GA analog for 24h. Treatment of GA analog modulates expression of anti-apoptotic
proteins such as Mcl-1, Bcl-2, and caspase 3.
-9 -8 -7 -6 -5 -4
0
50
100
150
GA
GA analog A
GA analog B
Concentration (Log(M))
%
 C
e
ll
 V
ia
b
il
it
y
RPMI 8226
-9 -8 -7 -6 -5 -4
0
50
100
150
GA
GA analog A
GA analog B
Concentration (Log(M))
%
 C
e
ll
 V
ia
b
il
it
y
U266
Drug resistance
Growth
Survival
Migration
MM cells
Inhibits angiogenesis
Induces apoptosis
Inhibits MM cell 
adhesion with BM 
cells
Gambogic acid
IL-6, VEGF, 
SDF1α, 
Inhibits cytokine circuits
Growth/survival stimuli
?
A
B
C
E
D
Figure 1. Intimate relationship between MM and BM
microenvironment. BMSCs secrete cytokine a growth factors,
these growth factors activate several pathways in MM. GA targets
these pathways.
A B
Figure 4:  Our data showed that GA and its analog  mediate their effects by targeting MM cells and the BM 
microenvironment. (A) GA targets CXCR4 receptor, (B) directly inhibits MM cell growth, (C) inhibits angiogenesis, 
(D) decrease cytokine production and sequelae such as osteoclastogenesis, and whether inhibits MM cell 
adhesion to BM accessory cells (E) will be explored.
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